Surmodics Management
Management criteria checks 2/4
Surmodics' CEO is Gary Maharaj, appointed in Dec 2010, has a tenure of 14.17 years. total yearly compensation is $3.67M, comprised of 17.7% salary and 82.3% bonuses, including company stock and options. directly owns 1.34% of the company’s shares, worth €6.33M. The average tenure of the management team and the board of directors is 6.8 years and 14.2 years respectively.
Key information
Gary Maharaj
Chief executive officer
US$3.7m
Total compensation
| CEO salary percentage | 17.7% |
| CEO tenure | 14.2yrs |
| CEO ownership | 1.3% |
| Management average tenure | 6.8yrs |
| Board average tenure | 14.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | n/a | n/a | -US$14m |
| Sep 30 2024 | US$4m | US$647k | -US$12m |
| Jun 30 2024 | n/a | n/a | -US$1m |
| Mar 31 2024 | n/a | n/a | US$14m |
| Dec 31 2023 | n/a | n/a | US$6m |
| Sep 30 2023 | US$4m | US$640k | -US$2m |
| Jun 30 2023 | n/a | n/a | -US$23m |
| Mar 31 2023 | n/a | n/a | -US$36m |
| Dec 31 2022 | n/a | n/a | -US$32m |
| Sep 30 2022 | US$3m | US$620k | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$13m |
| Mar 31 2022 | n/a | n/a | -US$10m |
| Dec 31 2021 | n/a | n/a | US$2m |
| Sep 30 2021 | US$3m | US$602k | US$4m |
| Jun 30 2021 | n/a | n/a | US$2m |
| Mar 31 2021 | n/a | n/a | US$7m |
| Dec 31 2020 | n/a | n/a | US$701k |
| Sep 30 2020 | US$3m | US$585k | US$1m |
| Jun 30 2020 | n/a | n/a | US$8m |
| Mar 31 2020 | n/a | n/a | US$7m |
| Dec 31 2019 | n/a | n/a | US$6m |
| Sep 30 2019 | US$2m | US$568k | US$8m |
| Jun 30 2019 | n/a | n/a | US$2m |
| Mar 31 2019 | n/a | n/a | -US$2m |
| Dec 31 2018 | n/a | n/a | -US$2m |
| Sep 30 2018 | US$2m | US$551k | -US$4m |
Compensation vs Market: Gary's total compensation ($USD3.67M) is above average for companies of similar size in the German market ($USD1.01M).
Compensation vs Earnings: Gary's compensation has increased whilst the company is unprofitable.
CEO
Gary Maharaj (61 yo)
14.2yrs
Tenure
US$3,665,496
Compensation
Mr. Gary R. Maharaj has been the Chief Executive Officer and President at Surmodics, Inc. since December 27, 2010. Mr. Maharaj served as the Chief Executive Officer and President at Arizant Inc. from 2006...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 14.2yrs | US$3.67m | 1.34% € 6.3m | |
| Senior VP of Finance & Information Technology and CFO | 6.8yrs | US$1.34m | 0.47% € 2.2m | |
| Senior VP of Legal | 4.8yrs | US$1.15m | 0.15% € 693.8k | |
| Senior VP & President of Medical Device Coatings | 20.3yrs | US$1.13m | 0.37% € 1.7m | |
| Senior VP & President of Vascular Interventions | 2.8yrs | US$1.52m | 0.24% € 1.1m | |
| Corporate Controller | 6.8yrs | no data | 0.057% € 268.9k | |
| Director of Corporate Development | no data | no data | no data | |
| Senior VP of Human Resources & President of In Vitro Diagnostics | 4.8yrs | US$970.92k | 0.43% € 2.0m |
6.8yrs
Average Tenure
59yo
Average Age
Experienced Management: SU6's management team is seasoned and experienced (6.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 14.2yrs | US$3.67m | 1.34% € 6.3m | |
| Independent Director | 14.1yrs | US$185.00k | 0.27% € 1.3m | |
| Independent Non-Executive Chair of the Board | 17.1yrs | US$234.00k | 0.14% € 658.0k | |
| Independent Director | 23.1yrs | US$176.50k | 0.20% € 954.9k | |
| Independent Director | 7.8yrs | US$181.50k | 0.094% € 443.6k |
14.2yrs
Average Tenure
68yo
Average Age
Experienced Board: SU6's board of directors are seasoned and experienced ( 14.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 03:42 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Surmodics, Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Daniel Owczarski | Avondale Partners |
| Michael Petusky | Barrington Research Associates, Inc. |